BSc., PhD. (Cardiff)
Molecular Biology – Gene regulation; Drug discovery- Atherosclerosis, Type II Diabetes and Cancer
Immune and Molecular Therapeutics
His lab focuses on deciphering the roles of transcription factors – members of peroxisome proliferator activated receptors (PPAR) and CCAAT/ enhancer binding proteins (C/EBP) – in regulating the gene expression of important proteins that are responsible in the development of type II diabetes mellitus, atherosclerosis and acute phase response. In addition, he is interested in using molecular biology-based approach in developing target-based high-throughput screening platform to screen for potential hits from natural products against type II diabetes mellitus and atherosclerosis as well as cancers. Such molecular targets include PCSK9 and SR-B1 for atherosclerosis as well as PPARγ for type II diabetes mellitus. He also works on the elucidation of the molecular mechanisms of action of apoptotic cell death exerted by small molecules on cancer cells.